Showing 341 - 360 results of 147,806 for search '(( a non decrease ) OR ( 10 ((((nn decrease) OR (a decrease))) OR (we decrease)) ))', query time: 1.32s Refine Results
  1. 341

    Table_1_Transcutaneous Electrical Acupoint Stimulation Decreases the Incidence of Postoperative Nausea and Vomiting After Laparoscopic Non-gastrointestinal Surgery: A Multi-Center Randomized Controlled Trial.doc by Wei Gao (2085)

    Published 2022
    “…</p>Results<p>Compared with the Sham treatment, the TEAS lowered the PONV incidence by 4.8% (29.4 vs. 34.2%, P = 0.036) and vomiting incidence by 7.4% (10.4 vs. 17.8%, P < 0.001). TEAS also lowered persistent nausea incidence and PONV scores and decreased PONV related complications and Quality of Recovery−40 scores (P < 0.05). …”
  2. 342

    Effect of iron mining tailings as a red ceramic additive for decreased sintering temperature by Igor Brumano Coelho Amaral (10472061)

    Published 2021
    “…We produced test pieces including a mixture of soil with 10 and 20% content of waste exposed to the sintering process at temperatures of 750, 850 and 950° C. …”
  3. 343
  4. 344
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350
  11. 351
  12. 352
  13. 353
  14. 354

    Table_1_Soil Properties Interacting With Microbial Metagenome in Decreasing CH4 Emission From Seasonally Flooded Marshland Following Different Stages of Afforestation.xlsx by Qian Zhang (49333)

    Published 2022
    “…We analyzed the structures of communities of methanogenic and methanotrophic microbes, quantification of mcrA and pmoA genes, the soil microbial metagenome, soil properties and CH<sub>4</sub> fluxes in afforested and non-afforested areas in the marshland of the Yangtze River. …”
  15. 355
  16. 356
  17. 357

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  18. 358
  19. 359
  20. 360